Clinical Trials
13 trialsNCT05063552 2026-06-03
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT07195734 2026-05-19
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05721755 2026-05-05
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT07441681 2026-05-04
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
Phase 3 Not yet recruiting
NCT07209189 2026-04-23
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT04030455 2026-03-09
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04862650 2026-02-10
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07400094 2026-02-10
NeoCamre-HN
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Not yet recruiting
NCT06084845 2024-07-25
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT01633541 2023-07-20
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02760667 2023-06-27
Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer
George Washington University
Phase 2 Unknown
NCT00158652 2011-11-08
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Completed